These contribute to burping volume even if the burps do not carry sulfur odor
Real-world data adds important context: Patients who discontinued semaglutide or tirzepatide within the first three months lost only an average of 3.6% of body weight and most of this regained quickly after stopping Patients who remained on treatment for 612 months achieved more significant losses (averaging 6.8%) and maintained results better after stopping 63% of patients who started Wegovy or Zepbound in early 2024 remained on therapy at one year up significantly from 40% in the 2023 cohort, reflecting improving support systems Long-term persistence remains a challenge: only about 14% of patients remain on semaglutide after three years Why Does Weight Come Back
Clinical wins, safety setbacks, generics pressure, and aggressive IP maneuvering are reshaping the competitive landscape at record speed
Certified 99% purity with full batch traceability
That's entirely procedural
However, some of the most significant interactions are with other GLP-1 drugs like Wegovy, the antiviral drug cidofovir, other diabetes medications like sulfonylureas or metformin, loop diuretics, quinolone antibiotics, and aminoglycoside antibiotics
